

# Special Issue

## Chronic Pain

### Message from the Guest Editor

The Clinical Pharmacogenetics Consortium (CPIC) provided guidelines on stratification of pro-opioids based on CYP2D6 function, suggesting generalized recommendations for poor and ultrarapid metabolizers. Variations in other genes have been implicated in determining response to opioids, including OPRM1, COMT, and ABCC1; however, no clinical guidelines or protocols have been developed. Upcoming CPIC recommendations expand on the role of variations in the CYP2C9 on NSAIDs. Alternative non-opioid treatment options for chronic pain include SNRIs, TCAs, antiepileptics, and cannabinoids, yet clinical protocols for evidence-based management of chronic pain have not been detailed for various types of chronic pain conditions, such as cancer pain, fibromyalgia, arthritis, IBD, and neuropathic pain. The *Journal of Personalized Medicine* is now opening a Special Issue that is fully devoted to evidence-based chronic pain management, with a call for papers involving basic, translational, and clinical research on this topic.

---

### Guest Editor

Dr. Ruslan Dorfman

Department of Anesthesia, McMaster University, Hamilton, ON, Canada

---

### Deadline for manuscript submissions

closed (20 December 2020)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/32852](https://mdpi.com/si/32852)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).